Vitamin K2 and D3 enter a randomized test against severe coronary calcification
Severe coronary artery calcification sits at the center of this protocol because it is not a cosmetic imaging finding; it is a marker of advanced atherosclerotic disease and a predictor of acute myocardial infarction and cardiovascular death. The trial asks a direct question with bedside relevance: can daily supplementation with vitamin K2 and vitamin D3 slow the progression of calcified coronary plaque in men and women who already carry a very high calcium burden?
The study is structured to answer that question with rigor. Four hundred participants with a coronary artery calcium score of at least 400 are being randomized in a 1:1 fashion to active supplementation or placebo, with follow-up planned for 2 years. The active regimen combines vitamin K2 at 720 µg/day with vitamin D3 at 25 µg/day. In a disease defined by cumulative arterial injury, a trial of this size and duration is designed to capture whether the calcific process can be altered measurably rather than merely discussed in theory.
Imaging progression is the central readout
The primary endpoint is progression in CAC score from baseline to 2 years. That choice places imaging at the heart of the protocol, because serial calcium scoring can track whether plaque calcification accelerates, stabilizes, or continues despite treatment. Cardiac CT scanning is scheduled at baseline and repeated after 12 and 24 months, allowing the investigators to map the trajectory of coronary calcification over time rather than relying on a single post-treatment snapshot.
A one-sentence fact stands out. The trial is built around progression, not simply presence, of coronary calcium.
Secondary outcomes expand the lens beyond the calcium score itself. Coronary plaque composition will be assessed, and cardiac events are also included among the secondary measures. Those endpoints matter because calcification is only one aspect of atherosclerotic biology; plaque composition can offer clues about structural stability, while clinical events connect imaging changes to patient-level consequences. A treatment that alters calcium accumulation without affecting plaque phenotype or events would still raise important questions about mechanism and clinical meaning.
Why vitamin K2 and D3 are being studied together
The rationale for combining vitamins K2 and D3 rests on their proposed role in calcification biology. The protocol frames supplementation as a possible protective strategy against progression of coronary artery calcification, and the central hypothesis is straightforward: vitamin K2 and D3 may slow the calcification process. In clinical terms, that means the intervention is being tested against the pathobiology of arterial mineralization itself, not just against symptoms or surrogate inflammatory markers.
Vitamin K2 has attracted interest because it is linked to proteins involved in calcium handling, while vitamin D3 is often studied in relation to musculoskeletal and cardiovascular biology. The protocol does not claim proof of benefit; it acknowledges a suggestion of protection and moves that idea into a randomized, double-blinded, placebo-controlled setting. In patients with established severe calcification, that transition from biologic plausibility to prospective testing is important. It separates hypothesis from practice.
Trial design aims to reduce bias in a high-risk cohort
This is a multicentre, double-blinded, placebo-controlled study, which gives it the methodological structure needed to evaluate a question that could otherwise be clouded by expectation and selection bias. Randomization in equal allocation helps balance measured and unmeasured characteristics between groups. Blinding limits the influence of patient and investigator expectations on follow-up assessment. The intention-to-treat principle is specified for analysis, preserving the randomized comparison even when real-world adherence proves imperfect.
Several exclusion criteria sharpen the safety and interpretability of the study population. Patients taking a vitamin K antagonist are excluded, as are those with coagulation disorders and those with prior coronary artery disease. Those exclusions are clinically sensible because vitamin K biology intersects with anticoagulation, and prior coronary disease could complicate the interpretation of calcification progression and event risk. By limiting the cohort to participants with severe CAC but without prior coronary artery disease, the trial tries to isolate a population in which progression can be observed cleanly.
A second one-sentence fact deserves emphasis. This is a protocol, not a results paper, and no efficacy signal is available yet.
Safety, ethics, and the limits of the current evidence base
The protocol states that there are so far no reported adverse effects associated with the use of vitamin K2. Even so, the absence of reported harm is not the same as proof of safety in a high-risk, two-year randomized cohort. That is precisely why the placebo-controlled design matters. Longitudinal follow-up can reveal whether the supplement combination is tolerated in a population already defined by advanced coronary calcification and whether any safety concerns emerge during sustained exposure.
Ethical oversight has already been secured. The protocol was approved by the Regional Scientific Ethical Committee for Southern Denmark and the Data Protection Agency, and the study will be conducted in accordance with the Declaration of Helsinki. The trial is registered under NCT05500443, which provides transparency around the planned methods and endpoints. Positive and negative findings are both slated for reporting, an important commitment in a field where nutritional interventions often accumulate enthusiasm faster than evidence.
The broader clinical question remains tightly focused: if calcification progression can be slowed, can the biology of atherosclerosis be nudged in a direction that matters for later infarction and mortality? The protocol does not answer that yet, but it sets up a disciplined test in a cohort where the signal, if present, should be visible on serial cardiac CT. What follows will depend on whether the calcium score curve separates between active treatment and placebo over the 24-month observation window.